SCHEMBL2840800

SCHEMBL2840800

O=C(Cc1ccc(F)cc1)Nc1ccc(C(C(=O)NO)c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.62
HDAC3 O15379 3/20 0.57
HDAC4 P56524 3/20 0.57
HDAC1 Q13547 3/20 0.57
HDAC7 Q8WUI4 3/20 0.57
HDAC2 Q92769 3/20 0.57
HDAC10 Q969S8 3/20 0.57
HDAC11 Q96DB2 3/20 0.57
HDAC8 Q9BY41 3/20 0.57
HDAC6 Q9UBN7 3/20 0.57
HDAC9 Q9UKV0 3/20 0.57
HDAC5 Q9UQL6 3/20 0.57
KLK7 P49862 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CYP3A4 P08684 2/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
CNR2 P34972 1/20 0.51
MEN1 O00255 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20490382 0.91 EPHX2 (0.61) GAAHDAC3HDAC4HDAC1HDAC7
SCHEMBL20490423 0.89 ALDH1A1 (0.57) GAAHDAC3HDAC4HDAC1HDAC7
SCHEMBL2839251 0.88 MEN1 (0.61) GAAHDAC3HDAC4HDAC1HDAC7
SCHEMBL2879924 0.84 ALDH1A1 (0.68) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2845019 0.82 HDAC4 (0.60) GAAHDAC3HDAC4HDAC1HDAC7
SCHEMBL10977876 0.81 GAA (0.83) GAASMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL10977880 0.81 GAA (0.83) GAAHDAC3HDAC1HDAC2SMN1; SMN2
SCHEMBL2839321 0.81 RAB9A (0.63) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20490599 0.80 EPHX2 (0.56) GAAHDAC3HDAC4HDAC1HDAC7
SCHEMBL2840181 0.79 BCHE (0.63) SMN1; SMN2MEN1KMT2AMAPK1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP claimed
CN-101679220-A Histone deacetylase inhibitor METHYLGENE INC 2010-03-24 CN claimed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US claimed
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
CN-101679220-A Histone deacetylase inhibitor METHYLGENE INC 2010-03-24 CN disclosed
EP-2139850-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-01-06 EP disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 GAA 328/4885HDAC3 3/4885HDAC4 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.